Showing results (181-190 of 219) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 PatientsTakami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.
Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2019
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Chan Gao, Megan Raymond, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabDavid F McDermott, Charles G Drake, Mario Sznol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Frontiers in Oncology|September 15, 2022
Adjuvant crizotinib in high-risk uveal melanoma following definitive therapyShaheer Khan, Jose Lutzky, Alexander N Shoushtari, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 2, 2017
Patient perspectives on ipilimumab across the melanoma treatment trajectoryElyse Shuk, Alexander N Shoushtari, Jason Luke, et al.
The Oncologist|October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue SarcomasRodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
Pageof 22